ArriVent BioPharma, Inc. (AVBP) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.04: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 4.25; Below-average business quality.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase... Read more
Sell if holding. Engine safety override at $27.04: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 4.25; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 88d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — ArriVent BioPharma, Inc.
Latest news
- Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43 — benzinga May 13, 2026 neutral
- ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies — benzinga May 11, 2026 negative
- ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate — benzinga May 11, 2026 negative
- ArriVent BioPharma Receives IND Application Clearance From FDA For ARR-002 Treatment For Ovarian And Endometrial Cancers — benzinga May 7, 2026 positive
- Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $45 — benzinga Apr 24, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.0% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.04: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 4.25; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $25.58. Score 5.2/10, moderate confidence.
Take-profit target: $36.49 (+34.9% upside). Prior stop was $25.58. Stop-loss: $25.58.
Quality below floor (1.6 < 4.0).
ArriVent BioPharma, Inc. trades at a P/E of N/A (forward -8.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover AVBP with a consensus score of 4.3/5. Average price target: $42.
What does ArriVent BioPharma, Inc. do?ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and...
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.